BGACF (BioNeutra Global) Cyclically Adjusted Revenue per Share: $0.79 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioNeutra Global Cyclically Adjusted Revenue per Share?

BioNeutra Global BGACF Cyclically Adjusted Revenue per Share is $0.79 as of Sep. 2024.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioNeutra Global's adjusted revenue per share for the three months ended in Sep. 2024 was $0.055. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.79 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-17), BioNeutra Global's current stock price is $0.0056. BioNeutra Global's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.79. BioNeutra Global's Cyclically Adjusted PS Ratio of today is 0.01.


BioNeutra Global  (OTCPK:BGACF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioNeutra Global's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.0056/0.79
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioNeutra Global Cyclically Adjusted Revenue per Share Related Terms


BioNeutra Global Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioNeutra Global's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNeutra Global Cyclically Adjusted Revenue per Share Chart

BioNeutra Global Annual Data
Trend Feb14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.47 0.13 0.69

BioNeutra Global Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.69 0.47 0.57 0.79

BGACF vs ARRT, BSFC, RTON: Cyclically Adjusted Revenue per Share Comparison

For the Packaged Foods subindustry, BioNeutra Global's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNeutra Global Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioNeutra Global's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioNeutra Global's Cyclically Adjusted PS Ratio falls into.



BioNeutra Global Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioNeutra Global's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.055/127.2847*127.2847
=0.055

Current CPI (Sep. 2024) = 127.2847.

BioNeutra Global Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.000 98.367 0.000
201503 0.105 99.789 0.134
201506 0.078 100.500 0.099
201509 0.037 100.421 0.047
201512 0.059 99.947 0.075
201603 0.075 101.054 0.094
201606 0.105 102.002 0.131
201609 0.133 101.765 0.166
201612 0.112 101.449 0.141
201703 0.119 102.634 0.148
201706 0.146 103.029 0.180
201709 0.158 103.345 0.195
201712 0.137 103.345 0.169
201803 0.165 105.004 0.200
201806 0.201 105.557 0.242
201809 0.139 105.636 0.167
201812 0.116 105.399 0.140
201903 0.139 106.979 0.165
201906 0.146 107.690 0.173
201909 0.169 107.611 0.200
201912 0.158 107.769 0.187
202003 0.111 107.927 0.131
202006 0.101 108.401 0.119
202009 0.095 108.164 0.112
202012 0.080 108.559 0.094
202103 0.056 110.298 0.065
202106 0.072 111.720 0.082
202109 0.065 112.905 0.073
202112 0.072 113.774 0.081
202203 0.067 117.646 0.072
202206 0.060 120.806 0.063
202209 0.053 120.648 0.056
202212 0.033 120.964 0.035
202303 0.047 122.702 0.049
202306 0.051 124.203 0.052
202309 0.042 125.230 0.043
202312 0.043 125.072 0.044
202403 0.039 126.258 0.039
202406 0.042 127.522 0.042
202409 0.055 127.285 0.055

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.79 mean?
BioNeutra Global (BGACF) has a Cyclically Adjusted Revenue per Share of $0.79 as of Sep. 2024. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioNeutra Global and its competitors.
Is BioNeutra Global's Cyclically Adjusted Revenue per Share too high?
BioNeutra Global's current Cyclically Adjusted Revenue per Share is $0.79.
How does BioNeutra Global's Cyclically Adjusted Revenue per Share compare to ARRT and BSFC?
BioNeutra Global's Cyclically Adjusted Revenue per Share of $0.79 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioNeutra Global and its competitors. BioNeutra Global's current Cyclically Adjusted Revenue per Share is $0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNeutra Global stock overvalued right now?
BioNeutra Global (BGACF) has a current Cyclically Adjusted Revenue per Share of $0.79. The current Cyclically Adjusted Revenue per Share is $0.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioNeutra Global (BGACF), the current Cyclically Adjusted Revenue per Share is $0.79 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioNeutra Global Business Description

Address 1101-1030 West Georgia Street, Vancouver, BC, CAN, V6E 2Y3
BioNeutra Global Corp is engaged in the research, development, production, and commercialization of food ingredients for neutraceutical, functional and mainstream foods, focusing on oligosaccharides. Its product portfolio provides ingredients for various food systems, that contribute to human nutrition and wellness in functional and healthy foods. Its prime product, VitaFiber IMO, is offered in both powder and syrup form. The company operates in Canada while generating sales revenue from various countries internationally. It has a single industry segment, manufacturing and trading of products. The majority of the revenue is derived from the United States.